Abstract
Since its inception in the mid-1980s of the 20th century testing for carbohydrate antigen 19-9 (CA 19-9) has raised expectation for an earlier diagnosis and accurate monitoring of several malignant diseases. After almost 30 years, the available evidences have confirmed the appropriateness and usefulness of determining CA 19-9 levels as a prognostic indicator and as a reliable tool for monitoring pancreatic and gastrointestinal cancer, but concerns have been raised about its applications in screening, which is actually not recommended, and in the diagnosis of malignancies, due to several interferences that limit the specificity and to the insufficient sensitivity of this marker. In this paper we aimed to review the basic concepts of CA 19-9 testing and its current applications, with a major focus on the most recent evidences dealing with assay interference, methods comparison and monitoring of malignant diseases. The prognostic value and monitoring recommendations for pancreatic, gastric and colorectal cancers are described in depth.
Conflict of interest statement
Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
References
1. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979;5:957–71.10.1007/BF01542654Search in Google Scholar PubMed
2. Magnani JL, Steplewski Z, Koprowski H, Ginsburg V. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res 1983;43:5489–92.Search in Google Scholar
3. Goonnetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2007;33:266–70.10.1016/j.ejso.2006.10.004Search in Google Scholar PubMed
4. Duffy MG, Sturgeon C, Lamerz R, Haglund C, Holubec VL, Klaptor R, etal. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol 2010;21:441–7.10.1093/annonc/mdp332Search in Google Scholar PubMed
5. Klapdor R, Aronsson AC, Duffy MJ, Nilsson O, Sturpeou C, Topolcau O, etal. Tumor markers in gastrointestinal cancers, EGTM recommendations. Anticancer Res 1999;19:2785–820.Search in Google Scholar
6. Trapè J, Filella X, Alsina-Donadieu M, Juan-Pereira L, Bosch-Ferrers A, Rigo-Bonnin R. Increased plasma concentrations of tumour markers in the absence of neoplasia. Clin Chem Lab Med 2011;49:1605–20.10.1515/CCLM.2011.694Search in Google Scholar PubMed
7. Sturgeon CM, Viljoen A. Analytical error and interference in immunoassay: minimizing risk. Ann Clin Biochem 2011;48: 418–32.10.1258/acb.2011.011073Search in Google Scholar PubMed
8. Inoue K, Okada K, Taki Y, Goto R, Kinomura S, Kaneta T, etal. Increase of serum CA 19-9 level without an evident lesion on conventional imaging is insufficient for justification of 18FDPET examination. Hepatogastroenterology 2008;55:46–9.Search in Google Scholar
9. Basso D, Meggiato T, Fabris C, Plebani M, Fogar P, Panozzo MP, etal. Alterations in bilirubin metabolism during extra- and intrahepatic cholestasis. Clin Investig 1992;70:49–54.10.1007/BF00422939Search in Google Scholar PubMed
10. Fabris C, Basso D, Piccoli A, Meggiato T, Del Favero G, Fogar P, etal. Role of local and systemic factors in increasing serum glycoprotein markers of pancreatic cancer. J Med 1991;22: 145–56.Search in Google Scholar
11. Basso D, Fabris C, Del Favero G, Piccoli A, Angonese C, Pasquali C, etal. How does liver dysfunction influence serum CA 19-9 in pancreatic cancer? Ital J Gastroenterol 1990;22:1–6.Search in Google Scholar
12. Kim HR, Lee CH, Kim YW, Han SK, Shim YS, Yim JJ. Increased CA 19-9 level in patients without malignant disease Clin Chem Lab Med 2009;47:750–4.10.1515/CCLM.2009.152Search in Google Scholar PubMed
13. Bertino G, Ardiri AM, Boemi P, Bruno CM, Valenti M, Mazzarino MC, etal. Meaning of elevated CA 19-9 serum levels in chronic hepatitis and HCV-related cirrhosis. Minerva Gastroenterol Dietol 2007;53:305–9.Search in Google Scholar
14. Molina V, Visa L, Conill C, Navarro S, Escudero JM, Auge JM, etal. CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer. Tumor Biol 2012;33:799–807.10.1007/s13277-011-0297-8Search in Google Scholar PubMed
15. Berth M, Bosmans E, Everaert J, Dierick J, Schiettekatte J, Anckaert E, etal. Rheumatoid factor interference in the determination of carbohydrate antigen 19-9 (CA 19-9). Clin Chem Lab Med 2006;44:1137–9.10.1515/CCLM.2006.205Search in Google Scholar PubMed
16. Liang Y, Yang Z, Ye W, Yang J, He M, Zhong R. Falsely elevated carbohydrate antigen 19-9 level due to heterophilic antibody interference but not rheumatoid factor: a case report. Clin Chem Lab Med 2009;47:116–7.10.1515/CCLM.2009.020Search in Google Scholar PubMed
17. Passerini R, Cassatella MC, Boveri S, Salvatici M, Radice D, Zorzino L, etal. The pitfalls of CA 19-9: routine testing and comparison of two automated immunoassays in a reference oncology center. Am J Clin Pathol 2012;138:281–7.10.1309/AJCPOPNPLLCYR07HSearch in Google Scholar PubMed
18. Osswald BR, Klee FE, Wysocki S. The reliability of highly elevated CA 19-9 levels. Dis Markers 1993;11:275–8.10.1155/1993/234238Search in Google Scholar PubMed
19. Ventrucci M, Pozzato P, Cipolla A, Uomo G. Persistent elevation of serum CA 19-9 with no evidence of malignant disease. Dig Liver Dis 2009;4:357–63.10.1016/j.dld.2008.04.002Search in Google Scholar PubMed
20. Kim BJ, Lee KT, Moon TG, Kang P, Lee JK, Kim JJ, etal. How do we interpret an elevated carbohydrated antigen CA 19-9 level in asymptomatic subjects? Dig Liver Dis 2009;41:364–9.10.1016/j.dld.2008.12.094Search in Google Scholar PubMed
21. Kannagi R. Carbohydrate antigen sialyl Lewis a – its pathophysiological significance and induction mechanism in cancer progression. Chang Gung Med 2007;30:189–209.Search in Google Scholar
22. Partyka K, Maupin KA, Brand RE, Haab BB. Diverse monoclonal antibodies against the CA 19-9 antigen show variation in binding specificity with consequences for clinical interpretation. Proteomics 2012;12:2212–20.10.1002/pmic.201100676Search in Google Scholar PubMed PubMed Central
23. Ørntoft TF, Holmes EH, Johnson PH, Hakomori S-I, Clausen H. Differential tissue expression of the Lewis blood group antigens: enzymatic, immunohistologic, and immunochemical evidence for Lewis a and b antigen expression in Le(a2b2) individuals. Blood 1991;77:1389–96.10.1182/blood.V77.6.1389.1389Search in Google Scholar
24. Hamada E, Taniguchi T, Baba S, Maekawa M. Investigation of unexpected CA 19-9 elevation in Lewis-negative cancer patients. Ann Clin Biochem 2012;49:266–72.10.1258/acb.2011.011213Search in Google Scholar PubMed
25. Narimatsu H, Iwasaki H, Nakayama F, Ikehara Y, Kudo T, Nishihara S, etal. Lewis and Secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients. Cancer Res 1998;58:512–8.Search in Google Scholar
26. Passerini R, Riggio D, Salvatici M, Zorzino L, Radice D, Sandri MT. Interchangeability of measurements of CA 19-9 in serum with four frequently used assays: an update. Clin Chem Lab Med 2007;45:100–4.10.1515/CCLM.2007.003Search in Google Scholar PubMed
27. Láulu SL, Roberts WL. Performance characteristics of five automated CA 19-9 assays. Am J Clin Pathol 2007;127: 436–40.10.1309/H52VET3M6P7GYWG1Search in Google Scholar PubMed
28. Hotakainen K, Tanner P, Alfthan H, Haglund K, Stenman U-H. Comparison of three immunoassays for CA 19-9. Clin Chim Acta 2009;400:123–7.10.1016/j.cca.2008.10.033Search in Google Scholar PubMed
29. Zur B, Holdenrieder S, Albers E, Waldenbach-Bruenagel G, Stoffel-Wagner B. Method comparison for CA 15-3, CA 19-9, and CA 125 determination using the new loci technique of Dimension Vista 1500 and Immulite 2000 XPI. J Immunoassay Immunochem 2012;33:435–45.10.1080/15321819.2012.666221Search in Google Scholar
30. Plebani M, Giacomini A, Beghi L, De Paoli M, Roveroni G, Galeotti F, etal. Serum tumor markers in monitoring patients: interpretation of results using analytical and biological variation. Anticancer Res 1996;16:2249–52.Search in Google Scholar
31. Duffy MJ. Role of tumor markers in patients with solid cancers: a critical review. Eur J Intern Med 2007;18:175–84.10.1016/j.ejim.2006.12.001Search in Google Scholar
32. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, etal. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10–30.10.3322/canjclin.55.1.10Search in Google Scholar
33. Tzeng CW, Fleming JB, Lee JE, Wang X, Pisters PW, Vauthey J-N, etal. Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. HPB (Oxford) 2012,14:365–72.10.1111/j.1477-2574.2012.00445.xSearch in Google Scholar
34. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, etal. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313–27.10.1200/JCO.2006.08.2644Search in Google Scholar
35. Yip D, Karapetis C, Strickland A, Steer CB, Goldstein D. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer [review]. Cochrane Database Syst Rev 2006;3:CD002093.10.1002/14651858.CD002093.pub2Search in Google Scholar
36. Halm U, Schumann T, Schiefke I, Witzigmann H, Mössner J, Keim V. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 2000;82:1013–6.10.1054/bjoc.1999.1035Search in Google Scholar
37. Stemmler J, Stieber P, Szymala AM, Schalhorn A, Schermuly MM, Wilkowski R, etal. Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? Onkologie 2003;26:462–7.10.1159/000072980Search in Google Scholar
38. Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer 2005;93:195–9.10.1038/sj.bjc.6602687Search in Google Scholar
39. Hess V, Glimelius B, Grawe P, Dietrich D, Bodoky G, Ruhstaller T, etal. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol 2008;9:132–8.10.1016/S1470-2045(08)70001-9Search in Google Scholar
40. Klapdor R, Bahlo M, Babinski A, Klapdor S. CA 19-9 serum concentrations – analysis of the serum kinetics during first-line therapy of pancreatic cancer in relation to overall survival. Anticancer Res 2010;30:1869–74.Search in Google Scholar
41. Tian F, Appert HE, Myles J, Howard JM. Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma. Ann Surg 1992;215:350–5.10.1097/00000658-199204000-00008Search in Google Scholar PubMed PubMed Central
42. Lundin J, Roberts PJ, Kuusela P, Haglund C. The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. Br J Cancer 1994;69:515–9.10.1038/bjc.1994.93Search in Google Scholar PubMed PubMed Central
43. Ishii H, Okada S, Nose H, Yoshimori M, Aoki K, Okusaka T. Prognostic factors in patients with advanced pancreatic cancer treated with systemic chemotherapy. Pancreas 1996;12:267–71.10.1097/00006676-199604000-00009Search in Google Scholar PubMed
44. Ziske C, Schlie C, Gorschlueter M, Glasmacher A, Mey U, Strehl J, etal. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 2003;89:1413–7.10.1038/sj.bjc.6601263Search in Google Scholar PubMed PubMed Central
45. Haas M, Laubender RP, Stieber P, Holdenrieder R, Bruns CJ, Wilkowski R, etal. Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer. Tumor Biol 2010;31:251–7.10.1007/s13277-010-0044-6Search in Google Scholar PubMed
46. Hallemeier CL, Botros M, Corsini MM, Haddock MG, Gunderson LL, Miller RC. Preoperative CA 19-9 level is an important prognostic factor in patients with pancreatic adenocarcinoma treated with surgical resection and adjuvant concurrent chemoradiotherapy. Am J Clin Oncol 2011;34:567–72.10.1097/COC.0b013e3181f946fcSearch in Google Scholar PubMed
47. Buenger S, Laubert T, Roblick UJ, Habermann JK. Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview. J Cancer Res Clin Oncol 2011;137:375–89.10.1007/s00432-010-0965-xSearch in Google Scholar PubMed
48. Berger AC, Meszoely IM, Ross EA, Watson JC, Hoffman JP. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol 2004;11:644–9.10.1245/ASO.2004.11.025Search in Google Scholar PubMed
49. Kang CM, Kim JY, Choi GH, Kim KS, Choi JS, Lee WJ, etal. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer. J Surg Res 2007;140:31–5.10.1016/j.jss.2006.10.007Search in Google Scholar PubMed
50. Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol 2012;3:105–19.Search in Google Scholar
51. Hata S, Sakamoto Y, Yamamoto Y, Nara S, Esaki M, Shimada K, etal. Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer. Ann Surg Oncol 2012;19: 636–41.10.1245/s10434-011-2020-9Search in Google Scholar PubMed
52. Humphris JL, Chang DK, Johns AL, Scarlett CJ, Pajic M, Jones MD, etal. for the NSW Pancreatic Cancer Network. The prognostic and predictive value of serum CA 19.9 in pancreatic cancer. Ann Oncol 2012;23:1713–22.10.1093/annonc/mdr561Search in Google Scholar PubMed PubMed Central
53. Goldstein D, Spry N, Cummins MM, Brown C, van Hazel GA, Carroll S, etal. on behalf of the Australasian Gastro-Intestinal Trials Group. The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localized pancreatic cancer. Br J Cancer 2012;106:61–9.10.1038/bjc.2011.526Search in Google Scholar PubMed PubMed Central
54. Rustin GJ, Nelstrop AE, McClean P, Brady MF, McGuire WP, Hoskins WJ, etal. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996;14:1545–51.10.1200/JCO.1996.14.5.1545Search in Google Scholar PubMed
55. Altwegg R, Ychou M, Guillaumon V, Thezenas S, Senesse P, Flori N, etal. Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer. World J Gastroenterol 2012;18:1357–64.10.3748/wjg.v18.i12.1357Search in Google Scholar PubMed PubMed Central
56. Sugiura T, Uesaka K, Kanemoto H, Mizuno T, Sasaki K, Furukawa H, etal. Serum CA 19-9 is significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma. J Gastronintest Surg 2012;16: 977–85.10.1007/s11605-012-1859-9Search in Google Scholar PubMed
57. Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, etal. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem 2010;56:e1–48.10.1373/clinchem.2009.133124Search in Google Scholar PubMed
58. Kwon OK, Yu W, Chung H. Prognostic value of postoperative CA19-9 normalization in patients with advanced gastric cancer. Hepato-Gastroenterology 2012;60: DOI: 10.5754/hge12585.10.5754/hge12585Search in Google Scholar PubMed
59. Takahashi Y, Takeuchi T, Sakamoto J, Touge T, Mai M, Ohkura H, etal. The usefulness of CEA and/or CA 19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. Gastric Cancer 2003;6:142–5.10.1007/s10120-003-0240-9Search in Google Scholar PubMed
60. Kim HJ, Lee K-W, Kim YJ, Oh D-Y, Kim JH, Im S-A, etal. Chemotherapy-induced transient CEA and CA 19-9 surges in patients with metastatic or recurrent gastric cancer. Acta Oncol 2009;48:395–0.10.1080/02841860802446761Search in Google Scholar PubMed
61. Qiu MZ, Lin JZ, Wang ZQ, Wang FH, Pan ZZ, Luo HY, etal. Cutoff value of carcinoembryonic antigen and carbohydrate antigen 19-9 elevation levels for monitoring recurrence in patients with resectable gastric adenocarcinoma. Int J Biol Markers 2009;24:258–64.10.1177/172460080902400407Search in Google Scholar
62. Choi SR, Jang JS, Lee JH, Roh MH, Kim MC, Lee WS, etal. Role of serum tumor markers in monitoring for recurrence of gastric cancer following radical gastrectomy. Dig Dis Sci 2006;51:2081–6.10.1007/s10620-006-9166-5Search in Google Scholar PubMed
63. Li Y, Yang Y, Lu M, Shen L. Predictive value of serum CEA, CA19-9 and CA72.4 in early diagnosis of recurrence after radical resection of gastric cancer. Hepato-Gastroenterol 2011;58:2166–70.Search in Google Scholar
64. Kim DH, Oh SJ, Oh CA, Choi MG, Noh JH, Sohn TS, etal. The relationships between perioperative CEA, CA 19-9, and CA 72-4 and recurrence in gastric cancer patients after curative radical gastrectomy. J Surg Oncol 2011;104:585–91.10.1002/jso.21919Search in Google Scholar PubMed
65. Ward U, Primrose JN, Finan PJ, Perren TJ, Selby P, Purves DA, etal. The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer. Br J Cancer 1993;67:1132–5.10.1038/bjc.1993.208Search in Google Scholar PubMed PubMed Central
66. Yang X-Q, Chen C, Wang F-B, Penc C-W, Li Y. Preoperative serum carcinoembryonic antigen, carbohydrate antigen 19-9 and carbohydrate antigen 125 as prognostic factors for recurrence-free survival in colorectal cancer. Asian Pacific J Cancer Prev 2011;12:1251–6.Search in Google Scholar
67. Lumachi F. Marino F, Orlando R, Chiara GB, Basso SM. Simultaneous multianalyte immunoassay measurement of five serum tumor markers in the detection of colorectal cancer. Anticancer Res 2012;32:985–8.Search in Google Scholar
68. de Haas RJ, Wichters DA, Flores E, Ducreux M, Lévi F, Paule B, etal. Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases. Ann Surg Oncol 2010;17:1010–23.10.1245/s10434-009-0887-5Search in Google Scholar PubMed PubMed Central
69. Holdenrieder S, Stieber P, Liska V, Treska V, Topolcan O, Dreslerova J, etal. Cytokeratin serum biomarkers in patients with colorectal cancer. Anticancer Res 2012;32:1971–6.Search in Google Scholar
70. Petrioli R, Licchetta A, Roviello G, Pascucci A, Francini E, Bargagli G, and the Multidisciplinary Oncology Group on Gastrointestinal Tumors. CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab. Cancer Invest 2012;30:65–71.10.3109/07357907.2011.629380Search in Google Scholar PubMed
71. Lin P-C, Lin J-K, Lin C-C, Wang H-S, Yang S-H, Jiang J-K, etal. Carbohydrate antigen 19-9 is a valuable prognostic factor in colorectal cancer patients with normal levels of carcinoembryonic antigen and may help predict lung metastasis. Int J Colorectal Dis 2012;27:1333–8.10.1007/s00384-012-1447-1Search in Google Scholar PubMed
72. Vestergaard EM, Hein HO, Meyer H, Grunnet N, Joergensen J, Wolf H, etal. Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin Chem 1999;45:54–61.Search in Google Scholar
73. Erden G, Barazi AO, Tezcan G, Yildirimkaya MM. Biological variation and reference change values of CA 19-9, CEA, AFP in serum of healthy individuals. Scand J Clin Lab Invest 2008;68:212–8.10.1080/00365510701601699Search in Google Scholar PubMed
©2013 by Walter de Gruyter Berlin Boston
